Teva to build in Russia; Hospital wastewater studied for drug elimination;

> Teva ($TEVA) will invest $50 million to build a pharma plant in Yaroslavl, Russia. Story

> A full-scale trial for the treatment of hospital wastewater to eliminate pharmaceuticals is under way in Europe. Article

> Drug Process Licensing Associates has filed a process patent for sitagliptin, the active ingredient in Merck's ($MRK) diabetes drug Januvia, protecting the manufacturing process for 20 years. Release

> In response to the shortage of talent in the pharmaceutical labor market, a Maltese University has launched a B.S. degree program covering manufacturing and sales. Item

> "Biofilters and single-use technology did particularly well," Pall's ($PLL) CEO told analysts, explaining why consumable sales grew almost 12% in the fourth quarter. More

> Rabies vaccinations that left two Delhi residents severely ill came from a new lot of vials; the remainder has been sealed. Story

> "CMO quality agreements are like marriage contracts. If you have to consistently pull them out when having conversations, then you are likely headed for divorce and should consider finding another CMO," says Susan Schniepp of OSO Biopharmaceuticals. Blog

> Nigerian pharmaceutical manufacturers that follow global standards and best practices are in line to be certified by WHO. Story

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.